SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol. 1994; 12: 20132021.
  • 2
    van den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology. 1998; 51: 11401145.
  • 3
    van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglioma: the European Organization of Research and Treatment of Cancer Brain Tumor Group study 26971. J Clin Oncol. 2003; 21: 25252528.
  • 4
    Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology. 1996; 46: 203207.
  • 5
    Buckner JC, Gesme D, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and and associations with chromosomal abnormalities. J Clin Oncol. 2003; 21: 251255.
  • 6
    Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003; 14: 17151721.
  • 7
    Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003; 21: 646651.
  • 8
    Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low grade glioma: clinical benefits and radiological response. Ann Oncol. 2003; 14: 17221726.
  • 9
    Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998; 90: 14731479.
  • 10
    Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytoma, and mixed oligoastrocytomas. J Clin Oncol. 2000; 18: 636645.
  • 11
    Bauman GS, Ino Y, Yeki K, Fisher BJ, Louis DN, Cairncross JG. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendroglioma. Int J Radiat Oncol Biol Phys. 2000; 48: 825830.
  • 12
    van den Bent MJ, Looijenga LHJ, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer. 2003; 97: 12761284.
  • 13
    Lantos PL, Bruner JM. Gliomatosis cerebri. In: KleihuesP, CaveneeWK, editors. Pathology and genetics. Tumours of the nervous system. Lyon: IARC, 2000: 9293.
  • 14
    Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 12771280.
  • 15
    Stock C, Ambros IM, Mann G, Gadner H, Amann G, Ambros PF. Detection of 1p36 deletions in paraffin section of neuroblastoma tissues. Genes Chromosomes Cancer. 1993; 6: 19.
  • 16
    Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related fators on mid-term to long-term cognitive sequelae in low grade gliomas: a comparative study. Lancet. 2002; 360: 13611368.
  • 17
    Gregor A, Cull A, Traynor A SM, Lander F, Love S. Neuropsychometric evaluation of long term survivors of adult brain tumours: relationship with tumour and treatment parameters. Radiother Oncol. 1996; 41: 5559.
  • 18
    Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001; 7: 839845.
  • 19
    Vos MJ, Hoekstra OS, Barkhof F, et al. Thallium-201 single-photon emmision computed tomography as an early predictor of outcome in recurrent glioma. J Clin Oncol. 2003; 21: 35593565.
  • 20
    Derlon JM, Chapon F, Noë MH, et al. Non-invasive grading of oligodendrogliomas: correlations between in vivo metabolic pattern and histopathology. Eur J Nucl Med. 2000; 27: 778787.
  • 21
    Ribom D, Eriksson A, Hartman M, et al. Positron emission tomograpy 11C-methionine and survival in patients with low-grade gliomas. Cancer. 2001; 92: 15411549.
  • 22
    Langen KJ, Ziemons K, Kiwit JCW, et al. 3-[123I]Iodo-α -methyltyrosine and [Methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med. 1997; 38: 517522.
  • 23
    Murphy PS, Viviers L, Abson C, et al. Monitoring temozolomide treatment in low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer. 2004; 90: 781786.
  • 24
    Karim ABMF, Afra D, Bleehen NM, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2002; 52: 316324.